Full Breakdown
Eli Lilly Launches Employer Connect to Enhance Access to Obesity Drugs
3/5/2026, 8:46:20 PM
Addressing Coverage Gaps in Obesity Treatment
Eli Lilly has introduced a new initiative called "Employer Connect," aimed at increasing employer coverage for obesity medications in the United States. This program seeks to tackle the significant barrier of access that many patients face due to inconsistent coverage and high costs associated with obesity treatments. According to Eli Lilly, approximately half of individuals with commercial insurance are unable to start or maintain treatment due to these coverage gaps. The list prices for Lilly's obesity drugs, including Zepbound and Mounjaro, can exceed $1,000 per month, making affordability a critical issue.
Features of the Employer Connect Program
The Employer Connect platform allows employers to customize their coverage options for obesity treatments. Employers can choose from over 15 independent program administrators, including GoodRx, Mark Cuban's Cost Plus Drug Company, and Teladoc Health, to design a benefits plan that meets their specific needs. The program offers Zepbound at a discounted price of $449 per month, which employers can subsidize to lower out-of-pocket costs for employees. Kevin Hern, senior vice president of Lilly Employer, emphasized that this initiative aims to provide employers with greater flexibility and transparency in managing obesity treatment benefits.
Impact on Employers and Employees
The launch of Employer Connect is particularly significant given the economic burden of obesity, which costs the U.S. economy over $1.7 trillion annually. Ilya Yuffa, executive vice president of Lilly USA, noted that for many individuals living with obesity, access to treatment is often dictated by insurance coverage and associated costs. The program is designed to alleviate some of these challenges by providing a structured approach for employers to offer obesity medications.
Criticism and Challenges
Despite the potential benefits, there are concerns regarding the overall effectiveness of the program. Critics argue that while the initiative may increase access for some employees, it does not address the broader systemic issues related to healthcare coverage and the high costs of medications. Additionally, the reliance on employer-sponsored plans may leave many individuals without adequate coverage, particularly those in smaller firms or those who are self-employed.
Verbatim Quotes
- “For far too many people living with obesity, starting or staying on treatment isn’t just a medical decision, it’s an access decision driven by coverage and cost,” — Ilya Yuffa, Executive Vice President, Lilly USA
- “This is our attempt to respond to some of the tensions that we've heard from employers that are keeping them on the sidelines, to try to address some of those in a way that might enable them to provide access to their employees to these medicines,” — Kevin Hern, Senior Vice President, Lilly Employer
What's Next for Employer Connect
Eli Lilly plans to expand the number of program administrators available through Employer Connect, enhancing the options for employers and potentially increasing the reach of obesity medications. The program's success will depend on how many employers choose to adopt these new coverage models in the coming months, with some expected to make decisions as early as 2027.
In summary, Eli Lilly's Employer Connect represents a strategic effort to improve access to obesity treatments for employees while addressing the concerns of employers regarding costs and coverage flexibility.
